Trial Profile
Phase-I Study of Bortezomib (VELCADE) Plus ICE (Ifosfamide, Carboplatin, Etoposide) for Patients With Relapsed Classical Hodgkin Lymphoma.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Carboplatin; Etoposide; Ifosfamide; Mesna
- Indications Hodgkin's disease
- Focus Adverse reactions
- 26 Jun 2012 Actual patient number is 14 according to ClinicalTrials.gov.
- 26 Jun 2012 Actual end date (Jun 2012) added as reported by ClinicalTrials.gov.
- 26 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.